sodium–glucose cotransporter 2 inhibitorsinsulinglucagon-like peptide-1 receptor agonistsmineralocorticoid receptor antagonistsPemafibrateACE inhibitorsglucagon-like peptide-1 receptor agonistangiotensin II receptor blockersstatinoral antihyperglycemic agents+4 more
…iated during follow-up—may still exist. At baseline, the use of sodium–glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and glucagon-like pept…